by Randy E. Miller | Sep 18, 2024 | FDA, FOIA, Hedge Funds, Medical Devices
FOIAengine: FDA Inspections Prompt FOIA Requests When CEO Quentin Blackford of iRhythm Technologies, Inc. (NASDAQ: IRTC) began his earnings call on August 1, his wearable heart monitor technology company had survived five years of market ups and downs and had...
by John A. Jenkins | Jul 10, 2024 | FOIA, Hedge Funds, Litigation, SEC
FOIA Requests Reveal Perils and Possibilities of the Consolidated Audit Trail, aka “Mass Surveillance” Imagine a time when anyone might be able to file a Freedom of Information Act request with the Securities and Exchange Commission for a complete audit-trail report...
by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
by John A. Jenkins | Apr 30, 2024 | FOIA, Hedge Funds, Stock Market
FOIAengine: Traders Had an Inside Track on the CPI. Journalists Used FOIA to Expose It. Today’s story is about the Bureau of Labor Statistics, which calculates the all-important Consumer Price Index. It’s also a cautionary tale about how a select few on Wall Street...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
